Cargando…

The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma

The small non-coding VTRNA1-1 (vault RNA 1–1) is known to confer resistance to apoptosis in several malignant cell lines and to also modulate the macroautophagic/autophagic flux in hepatocytes, thus highlighting its pro-survival role. Here we describe a new function of VTRNA1-1 in regulating in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferro, Iolanda, Gavini, Jacopo, Gallo, Stefano, Bracher, Lisamaria, Landolfo, Marc, Candinas, Daniel, Stroka, Deborah M., Polacek, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865259/
https://www.ncbi.nlm.nih.gov/pubmed/33960270
http://dx.doi.org/10.1080/15548627.2021.1922983
_version_ 1784655613185228800
author Ferro, Iolanda
Gavini, Jacopo
Gallo, Stefano
Bracher, Lisamaria
Landolfo, Marc
Candinas, Daniel
Stroka, Deborah M.
Polacek, Norbert
author_facet Ferro, Iolanda
Gavini, Jacopo
Gallo, Stefano
Bracher, Lisamaria
Landolfo, Marc
Candinas, Daniel
Stroka, Deborah M.
Polacek, Norbert
author_sort Ferro, Iolanda
collection PubMed
description The small non-coding VTRNA1-1 (vault RNA 1–1) is known to confer resistance to apoptosis in several malignant cell lines and to also modulate the macroautophagic/autophagic flux in hepatocytes, thus highlighting its pro-survival role. Here we describe a new function of VTRNA1-1 in regulating in vitro and in vivo tumor cell proliferation, tumorigenesis and chemoresistance. Knockout (KO) of VTRNA1-1 in human hepatocellular carcinoma cells reduced nuclear localization of TFEB (transcription factor EB), leading to a downregulation of the coordinated lysosomal expression and regulation (CLEAR) network genes and lysosomal compartment dysfunction. We demonstrate further that impaired lysosome function due to loss of VTRNA1-1 potentiates the anticancer effect of conventional chemotherapeutic drugs. Finally, loss of VTRNA1-1 reduced drug lysosomotropism allowing higher intracellular compound availability and thereby significantly reducing tumor cell proliferation in vitro and in vivo. These findings reveal a so far unknown role of VTRNA1-1 in the intracellular catabolic compartment and describe its contribution to lysosome-mediated chemotherapy resistance. Abbreviations: ATP6V0D2: ATPase H+ transporting V0 subunit d2; BafA: bafilomycin A1; CLEAR: coordinated lysosomal expression and regulation; CQ: chloroquine; DMSO: dimethyl sulfoxide; GST-BHMT: glutathionine S-transferase N-terminal to betaine–homocysteine S-methyltransferase; HCC: hepatocellular carcinoma; LAMP1: lysosomal associated membrane protein 1; LLOMe: L-leucyl-L-leucine methyl ester; MAP1LC3B/LC3: microtubule associated protein 1 light chain 3 beta; MAPK: mitogen-activated protein kinase; MITF: melanocyte inducing transcription factor; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ncRNA: non-coding RNA; RNP: ribonucleoprotein; SF: sorafenib; SQSTM1/p62: sequestosome 1; STS: staurosporine; tdRs: tRNA-derived RNAs; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: transcription factor EB; vtRNA: vault RNA transcript.
format Online
Article
Text
id pubmed-8865259
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88652592022-02-24 The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma Ferro, Iolanda Gavini, Jacopo Gallo, Stefano Bracher, Lisamaria Landolfo, Marc Candinas, Daniel Stroka, Deborah M. Polacek, Norbert Autophagy Research Paper The small non-coding VTRNA1-1 (vault RNA 1–1) is known to confer resistance to apoptosis in several malignant cell lines and to also modulate the macroautophagic/autophagic flux in hepatocytes, thus highlighting its pro-survival role. Here we describe a new function of VTRNA1-1 in regulating in vitro and in vivo tumor cell proliferation, tumorigenesis and chemoresistance. Knockout (KO) of VTRNA1-1 in human hepatocellular carcinoma cells reduced nuclear localization of TFEB (transcription factor EB), leading to a downregulation of the coordinated lysosomal expression and regulation (CLEAR) network genes and lysosomal compartment dysfunction. We demonstrate further that impaired lysosome function due to loss of VTRNA1-1 potentiates the anticancer effect of conventional chemotherapeutic drugs. Finally, loss of VTRNA1-1 reduced drug lysosomotropism allowing higher intracellular compound availability and thereby significantly reducing tumor cell proliferation in vitro and in vivo. These findings reveal a so far unknown role of VTRNA1-1 in the intracellular catabolic compartment and describe its contribution to lysosome-mediated chemotherapy resistance. Abbreviations: ATP6V0D2: ATPase H+ transporting V0 subunit d2; BafA: bafilomycin A1; CLEAR: coordinated lysosomal expression and regulation; CQ: chloroquine; DMSO: dimethyl sulfoxide; GST-BHMT: glutathionine S-transferase N-terminal to betaine–homocysteine S-methyltransferase; HCC: hepatocellular carcinoma; LAMP1: lysosomal associated membrane protein 1; LLOMe: L-leucyl-L-leucine methyl ester; MAP1LC3B/LC3: microtubule associated protein 1 light chain 3 beta; MAPK: mitogen-activated protein kinase; MITF: melanocyte inducing transcription factor; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ncRNA: non-coding RNA; RNP: ribonucleoprotein; SF: sorafenib; SQSTM1/p62: sequestosome 1; STS: staurosporine; tdRs: tRNA-derived RNAs; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: transcription factor EB; vtRNA: vault RNA transcript. Taylor & Francis 2021-05-07 /pmc/articles/PMC8865259/ /pubmed/33960270 http://dx.doi.org/10.1080/15548627.2021.1922983 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Research Paper
Ferro, Iolanda
Gavini, Jacopo
Gallo, Stefano
Bracher, Lisamaria
Landolfo, Marc
Candinas, Daniel
Stroka, Deborah M.
Polacek, Norbert
The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
title The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
title_full The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
title_fullStr The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
title_full_unstemmed The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
title_short The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
title_sort human vault rna enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865259/
https://www.ncbi.nlm.nih.gov/pubmed/33960270
http://dx.doi.org/10.1080/15548627.2021.1922983
work_keys_str_mv AT ferroiolanda thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT gavinijacopo thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT gallostefano thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT bracherlisamaria thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT landolfomarc thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT candinasdaniel thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT strokadeborahm thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT polaceknorbert thehumanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT ferroiolanda humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT gavinijacopo humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT gallostefano humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT bracherlisamaria humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT landolfomarc humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT candinasdaniel humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT strokadeborahm humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma
AT polaceknorbert humanvaultrnaenhancestumorigenesisandchemoresistancethroughthelysosomeinhepatocellularcarcinoma